

Article

Increased levels of circulating fatty acids are associated with protective effects against future cardiovascular events in non-diabetics

Muhammad Anas Kamleh, Olga McLeod, Antonio Checa, Damiano Baldassarre, Fabrizio Veglia, Karl Gertow, Steve E Humphries, Rainer Rauramaa, Ulf deFaire, Andries J Smit, Philippe Giral, Sudhir Kurl, Elmo Mannarino, Elena Tremoli, Angela Silveira, John Orvik, Anders Hamsten, and Craig E. Wheelock

J. Proteome Res., **Just Accepted Manuscript** • DOI: 10.1021/acs.jproteome.7b00671 • Publication Date (Web): 13 Dec 2017

Downloaded from <http://pubs.acs.org> on December 15, 2017

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.



Increased levels of circulating fatty acids are associated with protective effects against future cardiovascular events in non-diabetics

Short title: fatty acids protective against future cardiovascular events

Muhammad Anas Kamleh^{1†}, Olga McLeod^{2†}, Antonio Checa^{1†}, Damiano Baldassarre^{3,4}, Fabrizio Veglia³, Karl Gertow², Steve E. Humphries⁵, Rainer Rauramaa⁶, Ulf de Faire⁷, Andries J. Smit⁸, Philippe Giral⁹, Sudhir Kurl¹⁰, Elmo Mannarino¹¹ and Elena Tremoli^{3,4}, on behalf of the IMPROVE study group, Angela Silveira², John Örvik², Anders Hamsten^{2*}, Craig E. Wheelock^{1*}

[†]equal contribution, ^{*}corresponding author

Affiliations

1 Division of Physiological Chemistry 2, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.

2 Cardiovascular Medicine Unit, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet and Department of Cardiology, Karolinska University Hospital Solna, Stockholm, Sweden.

3 Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano.

4 Centro Cardiologico Monzino, I.R.C.C.S., Milan Italy.

5 Cardiovascular Genetics, Institute of Cardiovascular Science, University College of London, London, United Kingdom.

6 Foundation for Research in Health Exercise and Nutrition, Kuopio Research Institute of Exercise Medicine, Kuopio, Finland.

7 Division of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet and Department of Cardiology, Karolinska University Hospital Solna, Stockholm, Sweden.

8 Department of Medicine, University Medical Center Groningen, Groningen, the Netherlands.

9 Assistance Publique - Hopitaux de Paris; Service Endocrinologie-Metabolisme, Groupe Hôpitalier Pitie-Salpetriere, Unités de Prévention Cardiovasculaire, Paris, France.

10 Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio Campus.

11 Internal Medicine, Angiology and Arteriosclerosis Diseases, Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy.

Corresponding authors:

Craig Wheelock
Karolinska Institutet
MBB, Scheeles väg 2
17177 Stockholm, Sweden
Craig.Wheelock@ki.se
Tel +46 8 524 876 30

Anders Hamsten
Karolinska University Hospital in Solna
CMM, L8:03
17176 Stockholm Sweden
Anders.Hamsten@ki.se
+46 8 51773201

Keywords: Cardiovascular disease, diabetes, fatty acids, metabolomics, eicosanoids, endocannabinoids

Abstract

Cardiovascular disease (CVD) is a major cause of morbidity and mortality worldwide, particularly in individuals with diabetes. The current study objective was to determine the circulating metabolite profiles associated with the risk of future cardiovascular events, with emphasis on diabetes status. Non-targeted metabolomics analysis was performed by LC-HRMS in combination with targeted quantification of eicosanoids and endocannabinoids. Plasma from 375 individuals from the IMPROVE pan-European cohort were included in a case-control study design. Following data processing, the three metabolite datasets were concatenated to produce a single dataset of 267 identified metabolites. Factor analysis identified six factors that described 26.6% of the variability in the given set of predictors. An association with cardiovascular events was only observed for one factor following adjustment ($p=0.026$). From this factor, we identified a free fatty acid signature ($n=10$ lipids, including saturated, monounsaturated, and polyunsaturated fatty acids) that was associated with lower risk of future cardiovascular events in non-diabetics only ($OR=0.65$, $0.27-0.80$ 95% CI, $p=0.030$), whereas no association was observed among diabetic individuals. These observations support the hypothesis that increased levels of circulating omega-6 and omega-3 fatty acids are associated with protective effects against future cardiovascular events. However, these effects were only observed in the non-diabetic population, further highlighting the need for patient stratification in clinical investigations.

Introduction

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide (1), and is especially pronounced amongst individuals with diabetes (2). While multiple potential markers have been proposed for predicting future cardiovascular events, there is significant uncertainty regarding their ability to accurately predict risk (3). Metabolomics has been successfully applied to determine the circulating metabolic profile in an effort to link specific metabolites to the onset of CVD (4-8) and diabetes (9-11), as reviewed by Ruiz-Canela *et al.* (12) and Guasch-Ferré *et al.* (13). A recent large prospective study of 3 population-based cohorts employed high-throughput NMR-based metabolomics in combination with a targeted metabolomics platform to identify (sets of) biomarkers that improved CVD risk prediction (8). In the current study, we applied non-targeted high-resolution mass spectrometry to a pan-European study of cardiovascular disease (Carotid Intima Media Thickness [IMT] and IMT-Progression as Predictors of Vascular Events in a High Risk European Population; IMPROVE (14)). The study objective was to determine the metabolite profiles associated with the risk of future cardiovascular events. These metabolomics studies were complemented with targeted analyses of eicosanoids and endocannabinoids, which have known roles in CVD as well as diabetes (15-17). We stratified the study population by diabetic status given the importance of the reported biomarkers within the framework of the SURrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools (SUMMIT) consortium (18), which aimed to identify and characterize biomarkers for complications of diabetes.

Materials and Methods

Detailed methods are available in the Supplementary Information.

Study Population

The current study was based upon the original IMPROVE cohort, which is a multicentre longitudinal cohort study of 3711 subjects designed to identify the main determinants of cIMT in high-risk individuals (19). Between 2002 and 2004, men and women aged from 55 to 79 years with at least 3 vascular risk factors (VRF), but with no symptoms of cardiovascular disease, were recruited in 7 centers in 5 European countries (Finland, Sweden, the Netherlands, France, and Italy) and followed for about 3 years. Individuals were considered to possess a VRF when one of the following criteria was satisfied: male sex or at least 5 years after menopause for women; hypercholesterolemia (mean calculated LDL-C blood levels > 160 mg/dL or treatment with lipid lowering drugs); hypertriglyceridemia (triglycerides levels > 200 mg/dL after diet or treatment with triglycerides lowering drugs); hypoalphalipoproteinemia (HDL-C < 40 mg/dL); hypertension (diastolic blood pressure, DBP > 90 mmHg and/or systolic blood pressure, SBP >140 mmHg or treatment with anti-hypertensive drugs); diabetes or impaired fasting glucose (blood glucose level > 110 mg/dL or treatment with insulin or oral hypoglycaemic drugs); smoking habits (at least 10 cigarettes/day for at least thirty months); family history of cardiovascular diseases. The IMPROVE study exclusion criteria were: age under 55 or over 79 years; abnormal anatomical configuration of neck and muscles; marked tortuosity and/or depth of the carotid vessels, and/or uncommon location of arterial branches; personal history of myocardial infarction, angina pectoris, stroke, transient ischemic attack, aortic aneurysm or claudication; re-vascularization in carotid, coronary or peripheral arteries, congestive heart failure (III-IV NYHA Class); history of serious medical conditions that might limit longevity.

1
2
3 During the study span, 215 cardiovascular events were recorded, including
4 myocardial infarction, sudden cardiac death, angina pectoris, ischemic stroke, transient
5 ischemic attack, new diagnosis of intermittent claudication, heart failure, or any surgical
6 intervention or revascularization of coronary or peripheral arteries. The case-control matching
7 yielded 201 pairs, after excluding subjects for whom a mismatch was observed between the
8 diabetes status in the database and the pre-established criteria used to define diabetes in the
9 present report (diagnosis of diabetes and/or treatment with insulin or other hypoglycemic
10 drug, and/or fasting glucose ≥ 7 mmol/L at the baseline examination). The final cohort for
11 metabolomics analysis included 173 incident cases and 172 controls matched for recruitment
12 center, age, sex, diabetes status, insulin use, statin use and smoking (Figure 1). From each of
13 these individuals, blood sampling was performed after an overnight fast. EDTA plasma
14 samples were prepared and kept frozen at -80°C until used for centralized laboratory analyses
15 (at the Karolinska Institutet, Sweden) (19). Ethics committee approvals for the study were
16 obtained in each of the 7 recruiting centers and the study followed the respective institutional
17 guidelines. Written informed consents were obtained from all participants. Informed consent
18 for the IMPROVE study includes assessments of CVD risks based on blood samplings for
19 later analyses of blood based risk markers and genetic variants as well as ultrasound
20 investigations of the carotids.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 *Metabolomics analysis*

45 Plasma samples were analyzed using liquid chromatography coupled to high-resolution mass
46 spectrometry (LC-HRMS) as previously published (20), and described in the Supplemental
47 Information. Briefly, EDTA plasma samples (400 μl) were thawed on ice and split into three
48 different extraction methods. For reversed-phase metabolomics analysis, 50 μl of plasma were
49 protein-precipitated with 3:1 volumes of pre-chilled methanol. For hydrophilic interaction
50
51
52
53
54
55
56
57
58
59
60

1
2
3 liquid chromatography (HILIC) metabolomics analysis, 50 μ l of plasma were protein-
4
5 precipitated with 4:1 volumes of acetonitrile. Samples were vortexed, centrifuged, and the
6
7 supernatant was transferred and stored at -80°C until the day of analysis. For lipid mediator
8
9 analysis, solid phase extraction (SPE) was used to extract lipid mediators from 250 μ l plasma
10
11 as previously published (21, 22). Eicosanoids and endocannabinoids were extracted with
12
13 Waters Oasis HLB (60 mg) SPE cartridges, eluted, and extracts were dried and stored at -
14
15 80°C until the day of analysis.

16
17
18 For metabolomics, samples were analysed using an Ultimate 3000 UHPLC and a Q-
19
20 Exactive Orbitrap mass spectrometer (ThermoFisher, Waltham, USA). For reversed-phase
21
22 chromatography, 20 μ l of sample was injected on a Thermo Accucore aQ RP C18 column
23
24 (150×2.1 mm, $2.7\mu\text{m}$ particle size) and analyzed as described in the Supplemental
25
26 Information. For HILIC chromatography, 12.5 μ l of sample was injected on a Merck-Sequant
27
28 ZIC-HILIC column (150×4.6 mm, $3.5\mu\text{m}$ particle size) fitted with a Merck Sequant ZIC-
29
30 HILIC guard column (20×2.1 mm) and analyzed as described in the Supplemental
31
32 Information. Mass spectrometry data were acquired (full scan mode) in both positive and
33
34 negative ionization modes (an independent run for each polarity), with a resolution of 70000
35
36 at 400 m/z .

37
38
39 Eicosanoid (21) and endocannabinoid (22) separation were performed as previously
40
41 published, using an Acquity UPLC and a XEVO-TQS triple quadrupole (Waters, Milford,
42
43 USA), with some modifications. Briefly, eicosanoid and endocannabinoid separation were
44
45 separately performed using an ACQUITY UPLC BEH (Ethylene Bridged Hybrid) C18
46
47 Column (130\AA , $1.7\mu\text{m}$, 2.1 mm X 150 mm) equipped with a pre-column (ACQUITY UPLC
48
49 BEH C18 VanGuard Pre-column, 130\AA , $1.7\mu\text{m}$, 2.1 mm X 5 mm) as described in the
50
51 Supplemental Information.
52
53
54
55
56
57
58
59
60

Data processing

MSconvert was used to convert and centroid the raw files to mzXML (23). All chromatograms were evaluated using the open source software package XCMS (24) performed under the package R. Two preliminary approaches were followed for metabolite annotation. Accurate mass and retention time (AMRT) approach was used to compare the physical parameters of accurate mass and retention time of authentic reference standards to those obtained in the metabolomics analysis. The second approach was a putative annotation (AM) based on matching the m/z signals obtained from the metabolomics analysis with those of entries in the human metabolome database (HMDB) (25). Metabolites of interest identified by factor analysis were later subjected to an MS/MS experiment (on the pooled QC sample). The method of identification for each metabolite is reported in Table S1.

Each sample was subjected to analysis in six different, but overlapping methods. To avoid the redundant reporting of the same metabolic signals, an in-house script (VBA-Excel) was used to filter metabolites reported in more than one method. The method of choice was the method with the least analytical variance judged by the coefficient of variance for the QC samples. After imputation of zero values with half the minimum recorded intensity, all metabolomics and background data were combined in one dataset for statistical analysis.

Statistical analysis

The computer software STATA version 11.2 (StataCorp LP, College Station, TX, USA) was used to conduct statistical analysis. Cluster analysis was performed in RStudio (Version 0.98.1062, RStudio, Boston, MA, USA). Forest plots were created using Forest Plot Viewer (SRA International, Inc., Durham, NC, USA). Baseline characteristics were reported as median (interquartile range) for continuous and as count (%) for binary variables. Fisher's exact test for parametric data and the Mann-Whitney U test for nonparametric data were used

1
2
3 for comparison between 2 groups. Nonparametric data were log-transformed prior to factor
4
5 analysis and/or regression. A two-sided p-value of 0.05 was considered significant. Principal
6
7 component analysis (PCA) was performed on the univariate (UV)-scaled log₁₀ of the data
8
9 using SIMCA v14.0 (MKS Umetrics, Sweden).

11
12 Metabolomics measurements contained two types of missing data, which were
13
14 treated differently. Values below the lowest calibration point were replaced with half the limit
15
16 of detection (LOD) for that metabolite. True missing values appeared if peaks were missing
17
18 for a reason of analytical failure. Metabolites with >25% of values below the LOD were
19
20 excluded from the analysis.

22
23 In order to identify a set of uncorrelated factors we performed factor analysis
24
25 with varimax (orthogonal) rotation. The purpose of factor analysis is to reduce the number of
26
27 latent variables (or dimensions), which can explain the common variance and correlation of a
28
29 larger set of original variables. Factor analysis allows identification of factors that account for
30
31 inter-relationships between these variables (26). The rationale for rotation is to maximize
32
33 factor loadings for selected factors whereas keeping the total variability described by the
34
35 combination of these factors. Scree plot for eigenvalues vs. components was examined to
36
37 determine the number of factors to retain (Figure S1). The number of factors to be included in
38
39 the analysis corresponded to the "elbow" in the scree plot. Based on a common rule of thumb
40
41 significant factor loading is considered to be >0.4, which was therefore the cut-off set for
42
43 factor loadings (26, 27). Clustering of metabolites was performed using hierarchical
44
45 clustering (Euclidean distances with Ward's method). In principle, Ward's method estimates
46
47 the distance between two clusters measured by ANOVA sum of squares and joins clusters to
48
49 maximize the likelihood, so called minimum variance method.

52
53 Association between these factors and incident cardiovascular events was first
54
55 assessed by conditional logistic regression analysis for matched pairs in univariate model and

1
2
3 with further adjustment for age, body mass index (BMI), anti-hypertension treatment (HT),
4 high-density lipoprotein (HDL) cholesterol, and anti-platelet medication. Association between
5 individual components and incident cardiovascular events was also analyzed in conditional
6 logistic regression and results were presented in the form of a forest plot. To evaluate the
7 relationship between the significant factor and its components with time to incident
8 cardiovascular events we used Cox proportional hazard regression with adjustment for age,
9 gender, and population substructure (assessed by multi-dimensional scaling 1, MSD1).
10 Hazard ratios were presented per one standard deviation of the predictor. All regression
11 models were stratified by diabetes status. The reported p-values for the metabolites identified
12 by factor analysis were not corrected for multiple hypothesis testing because they are highly
13 correlated metabolites identified in a single factor analysis.
14
15
16
17
18
19
20
21
22
23
24
25

26 The ability of Factor 1 and individual metabolites within this factor to predict short-
27 term progression of asymptomatic atherosclerosis was assessed by linear regression to change
28 over time in cIMT (cIMT progression) and inter-adventitia common carotid artery diameter
29 (ICCAD), where ICCAD was measured in plaque-free areas. Progression was an estimate of
30 change over follow-up time assessed by linear regression using measurements obtained at
31 baseline, and after 15 and 30 months (28). The linear regression was stratified by diabetes
32 status and adjusted for age, gender and corresponding baseline measurement of the carotid
33 artery segment. For Factor 1, an extended model also included MDS1, presence of
34 hypertension, blood glucose, ever smoking, lipid-lowering medication, anti-platelets use and
35 angiotensin receptor blockers use.
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 **Results**

51 The baseline characteristics of the study population according to the presence of diabetes are
52 summarized in Table 1. Among both diabetics and non-diabetics, the cases showed less
53
54
55
56
57
58
59
60

1
2 favorable anthropometric and metabolic profiles, and used more medication compared to the
3 controls. Case-control differences were accentuated among the individuals with diabetes.
4
5

6
7 Following data processing, the non-targeted metabolomics profiling yielded 1978
8 unique features, of which 270 were matched to chemical reference standards by accurate mass
9 and retention time. Of the 270 metabolites, 51 had >25% of the values below the limit of
10 detection. These compounds were excluded to give 219 identified metabolites. The remaining
11 1708 features were annotated putatively. A total of 104 lipid mediators from the eicosanoid
12 and endocannabinoid platforms were screened, of which 48 compounds were present above
13 the limit of quantification. These lipid mediators are generally present at concentrations too
14 low to be detected by metabolomics, and were therefore quantified using targeted methods.
15
16 The metabolomics and lipid mediator datasets were concatenated to produce a single dataset
17 of 267 metabolites included in the analyses described below. The full list of reported
18 metabolites is provided in Tables S1-S3. The potential for collection center bias was
19 examined via PCA analysis (Figure S2). No distinguishable clusters were observed on a
20 collection center basis (Figure S2A). However, samples collected in the Nordic countries
21 were distinct from the rest of Europe (Figure S2B). Accordingly, analyses were matched by
22 center to control for potential bias.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 The metabolite levels were compared between cases and controls, and no significant
40 patterns were observed in the 267 reported metabolites (Table S4). Accordingly, the data were
41 further analyzed by factor analysis. Analysis of the scree plot showed that six factors had
42 eigenvalues greater than the average eigenvalue (Figure S1). Accordingly, six factors were
43 retained after the varimax orthogonal rotation for the primary analysis. The six factors
44 described 26.6% of the total variability in the given set of predictors (Table S5). Amongst the
45 diabetics, there was no significant association between any of the six factors and
46 cardiovascular events (Table 2). In non-diabetics, two of the factors were significantly
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 associated with cardiovascular events at $p < 0.05$. Following adjustment for BMI, hypertension,
3 HDL cholesterol and anti-platelet medication, only Factor 1 (F1) remained significant
4 ($p = 0.026$) (Table 2). F1 contained 39 metabolites (Figure S3), the majority of which were free
5 fatty acids ($n = 10$, Figure 2) or their downstream metabolic products (*e.g.*, eicosanoids [$n = 19$],
6 endocannabinoids [$n = 5$]). The free fatty acids in F1 included polyunsaturated (PUFAs),
7 monounsaturated (MUFAs) and saturated fatty acids (SAT) (Figure S4). In non-diabetics,
8 high concentrations of free fatty acids were associated with lower odds to suffer
9 cardiovascular events (OR=0.65, 0.27-0.80 95% CI, $p = 0.030$), whereas no association was
10 observed among diabetic individuals (Figure 2). A similar trend was observed in Cox
11 proportional hazard regression for the F1 free fatty acids. F1 associated with longer time to
12 incident cardiovascular events in the non-diabetic group (HR=0.80, 0.65-0.97 95% CI,
13 $p = 0.024$) (Table 3). All free fatty acids measured were associated with a protective effect in
14 non-diabetic individuals.

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31 In the non-diabetic group, pairwise Spearman rank correlation analysis between the
32 six selected metabolic factors and cIMT measurements identified an association between
33 Factor 2 and all IMT readouts at baseline, as well as baseline ICCAD, which disappeared
34 after adjusting for age, gender and MDS1. Also in non-diabetics, a significant inverse
35 correlation was observed between Factor 3 and progression of Bulb- IMT_{mean} ($r = -0.23$, $p =$
36 0.002), which disappeared after further adjustments for cardiovascular risk factors and
37 medication ($\beta = -0.011$, $p = 0.067$). Associations between F1 and cIMT variables were
38 essentially non-significant. However, a significant correlation was found between F1 and
39 ICCAD change over time in non-diabetes, tested in linear regression with adjustment for
40 MDS1, cardiovascular risk factors (hypertension, blood glucose, ever smoking) and
41 medication (lipid-lowering drugs, angiotensin II receptor blockers and anti-platelets) ($\beta =$
42 -0.008 , $p = 0.001$) (Table S6). To identify the major effects for association with ICCAD change
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 over time among metabolites included in F1, we ran linear regression analysis for each
4
5 component (Table 4). The strongest association was observed with linoleic acid-derived
6
7 metabolites, including: 12(13)-epoxy octadecanoic acid (EpOME; $\beta=-0.018$, $p=0.001$), 9- and
8
9 13-hydroxyoctadecadienoic acid (9-HODE and 13-HODE; $\beta=-0.017$, $p=0.002$ and $\beta=-0.018$,
10
11 $p=0.001$, respectively), as well as 13-keto-octadecadienoic acid (13-KODE; $\beta=-0.014$,
12
13 $p=0.002$). Another group of interesting compounds associated with the dynamics of ICCAD
14
15 were N-stearoyl taurine ($\beta=-0.008$, $p=0.001$) and N-palmitoyl taurine ($\beta=-0.011$, $p=0.009$).
16
17
18
19

20 Discussion

21
22 In the present report, non-targeted metabolomics analyses of plasma from a subset of the
23
24 IMPROVE cohort identified a signature of free fatty acids associated with lower risk of future
25
26 cardiovascular events in non-diabetic subjects. These observations corroborate the results
27
28 recently reported by Würtz *et al.* (8) in a large prospective discovery cohort of 7,256
29
30 individuals, replicated in two other cohorts of 2,622 and 3,563 individuals. The two studies
31
32 had similar objectives; however, Würtz *et al.* (8) did not directly examine the effect of
33
34 diabetes. The IMPROVE study recruited subjects at high-risk of CVD, resulting in a cohort
35
36 with elderly participants (mean age 64 years) and 30% prevalence of diabetes. Based upon the
37
38 high prevalence of diabetes, and within the framework of the SUMMIT consortium, our
39
40 analyses were stratified by diabetes status. We observed that the risk for future cardiovascular
41
42 events differed significantly between the two strata, and that omega-6 fatty acids were
43
44 significantly associated with lower risk of future cardiovascular events only in non-diabetics.
45
46 Würtz *et al.* (8) identified omega-6 fatty acids to be significantly associated with lower risk
47
48 of future cardiovascular events (HR=0.89) over 15 years of follow-up in a large population
49
50 with a lower diabetes prevalence (~7.8%), which potentially explains the lack of reported
51
52 diabetes-related differences.
53
54
55
56
57
58
59
60

1
2
3 We also found that circulating levels of MUFAs, herein represented by palmitoleic,
4 oleic, and mead acids, associated with lower risk of cardiovascular events in non-diabetic
5 individuals. This finding agrees with earlier reports in which dietary MUFAs were shown to
6 directly correlate with the circulating levels (29), and with a favorable lipoprotein profile and
7 thus lower risk of CVD (30, 31). By contrast, Würtz *et al.* (8) reported that increased levels of
8 MUFAs were associated with a slightly higher risk for cardiovascular events (HR=1.17). The
9 protective effect that we observed in relation to increased levels of circulating fatty acids is
10 not restricted to one type of fatty acid, but includes PUFAs, MUFAs and SATs, with both
11 omega-6 and omega-3 fatty acids.
12
13
14
15
16
17
18
19
20
21

22 There are limited studies to date that perform metabolomics profiling in association
23 with incident CVD. The disparity in analytical approaches and metabolic coverage in the
24 utilized methods makes it challenging to directly compare studies. However, many of the
25 reported studies have observed that levels of circulating free fatty acids are associated with
26 the incidence of cardiovascular events (12). The exact fatty acid species as well as the
27 trajectory and magnitude of the shift vary with the reported study. Würtz *et al.* (8), as well as
28 the current study, focused on European populations and observed that increased levels of
29 omega-6 and omega-3 circulating fatty acids are associated with lower risk of future
30 cardiovascular events. In a Chinese population, circulating long-chain omega-3 fatty acids
31 and stearic acid were associated with lower risk of acute myocardial infarction, while
32 arachidonic acid levels were associated with a higher risk (32, 33). Of particular interest to the
33 current study was the observation that inclusion of oxylipin metabolites of arachidonic acid
34 did not affect the observed odds ratios (32). A detailed metabolomics investigation of a
35 German prospective cohort concluded that metabolites of the arachidonic acid pathway are
36 independently associated with risk of myocardial infarction in healthy adults (34).
37 Accordingly, the exact putative role of omega-6 and omega-3 derived lipid mediators (*e.g.*,
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 oxylipins, eicosanoids) in future cardiovascular events is unclear. There is subsequently
4
5 interest in measuring these low abundance lipid mediators when performing metabolomics
6
7 studies. Unfortunately, most general metabolomics profiling methods, and especially
8
9 metabolomics kits, do not detect these compounds, highlighting the need for targeted methods
10
11 in combination with metabolomics approaches. In addition, none of the studies listed above
12
13 stratified the reported population by diabetic status, which in light of the current study may
14
15 further confound the reported observations.
16

17
18 Although not a primary goal, we also analyzed the relationships between
19
20 metabolomics factors and carotid artery ultrasound measurements taken in the participants at
21
22 the baseline and in progression over 3 years of follow-up. In the IMPROVE study, the
23
24 progression of the maximum IMT detected after 15 months in the whole carotid tree
25
26 regardless of location (Fastest- $IMT_{(max-progr)}$) was significantly associated with the risk of
27
28 subsequent vascular events, whereas none of the other cIMT measures showed predictive
29
30 value (35). In the present study, the only significant association found was between F1 and
31
32 lower change over time in ICCAD in non-diabetics. ICCAD measured in plaque free areas is
33
34 assumed to reflect carotid expansion due to atherosclerosis and correlates with several
35
36 vascular risk factors. Interestingly, the protective associations between F1 and change in
37
38 ICCAD were driven by metabolic products of linoleic acid (12[13]-EpOME and 9[10]-
39
40 EpOME, 9-HODE, 13-HODE and 13-KODE) and taurine derivatives (N-stearoyl taurine and
41
42 N-palmitoyl taurine) (Table 4). The data on linoleic acid (and its derivatives) are unclear, but
43
44 a recent meta-analysis reported a suggestive relationship between dietary linoleic acid and
45
46 diabetes as well as CVD (36). Taurine, an abundant amino acid-like compound distributed
47
48 throughout human tissues, has a long list of biological activity including atheroprotective,
49
50 anti-inflammatory and anti-obesity effects (37, 38). Taurine has even been studied in relation
51
52 to cardiovascular prevention and obesity, although the effects of taurine ingestion in humans
53
54
55
56
57
58
59
60

1
2
3 remain unclear (37, 38). The metabolic effects of palmitic and stearic conjugates have not
4
5 been well studied and are unclear in the current context.
6

7 All participants of the present study were Europeans, which, to some extent,
8
9 precludes generalization of the observations to other populations. Another limitation is the
10
11 relatively small size, particularly of the diabetes subset, and lack of a replication cohort. The
12
13 current study does confirm previous similar results in larger populations (8); but suggests that
14
15 those findings are not applicable to entire populations. In addition, there is a potential bias in
16
17 the metabolites identified via metabolomics. While the method is comprehensive, there is a
18
19 possibility of metabolites not detected with the current method being of interest in
20
21 understanding cardiovascular risk. This potential metabolite bias does not affect the accuracy
22
23 of the reported results, but simply highlights that there may be additional biochemical
24
25 information of interest. In summary, the lack of protective effects observed for any of the
26
27 measured fatty acids, with respect to occurrence of cardiovascular events among diabetic
28
29 participants, calls for further studies into the increased CVD risk in these patients. In addition,
30
31 these findings highlight the utility of stratifying populations on multiple clinical and
32
33 physiological factors (*e.g.*, diabetic status, sex, therapeutic response). This type of analysis is
34
35 an important component of stratified medicine, as demonstrated by the reported observation
36
37 that the protective effects of circulating fatty acids is only observed in a non-diabetic sub-
38
39 group, which can have repercussions in study design and statistical analysis as well as the
40
41 primary study findings.
42
43
44
45
46
47

48 **Supporting Information**

49
50 The following files are available free of charge at ACS website <http://pubs.acs.org>:
51
52 Kamleh et al_Supporting Information_Methods. PDF file containing an extended methods
53
54 description and supporting data including Figures S1-S4 and Tables S5-S6.
55
56
57
58
59
60

1
2
3 Kamleh et al_Supporting Information_Metabolite Database. Excel file containing Tables S1-
4
5 S4, which provide a list of all metabolites reported in the current study.
6
7

8 9 **Funding**

10
11 SUMMIT was funded by the Innovative Medicines Initiative Joint Undertaking under grant
12
13 agreement no. 115006, resources of which are composed of financial contribution from the
14
15 European Union's Seventh Framework Programme (FP7/2007-2013) and in-kind contribution
16
17 from EFPIA companies. The IMPROVE study was supported by the European Commission
18
19 (Contract number: QLG1- CT- 2002- 00896), Ministero della Salute Ricerca Corrente, Italy,
20
21 the Swedish Heart-Lung Foundation, the Swedish Research Council (Grant numbers 8691 and
22
23 0593), the Foundation for Strategic Research, the Stockholm County Council (Grant number
24
25 562183), the Academy of Finland (Grant number 110413) and the British Heart Foundation
26
27 (Grant number PG008/08). CEW was funded by the Swedish Heart-Lung Foundation (Grant
28
29 numbers 20130447 and 20120453).
30
31
32
33
34

35 **Author Contribution**

36
37 MAK, OM, JÖ, AH and CEW conceived the study; clinical samples were acquired by DB,
38
39 FV, SEH, RR, UdF, AJS, PG, SK, EM, ET and AH; metabolomics data were acquired by
40
41 MAK and AC; statistical analysis was performed by MAK, OM, AC and JÖ; data
42
43 interpretation was performed by MAK, OM, AC, KG, AS, JÖ, AH and CEW; OM, AC, AS
44
45 and CEW prepared the tables and figures; and the manuscript was written by OM, AC, AS,
46
47 JÖ and CEW. All authors reviewed the final draft of the manuscript and gave final approval
48
49 of the version to be published.
50
51
52
53

54 **Competing Interests**

55
56
57
58
59
60

1
2
3 The authors declare that there are no competing interests associated with the manuscript.
4
5

6
7 **Abbreviations**

8
9 CVD, Cardiovascular diseases; CV, coefficient of variance; EpOME, epoxy octadecanoic
10 acid; HODE, hydroxyoctadecadienoic acid; HRMS, High resolution mass spectrometry;
11
12 HILIC, Hydrophilic Interaction Liquid Chromatography; HMDB, human metabolome
13 database; HR, hazard ratio; ICCAD, inter-adventitia common carotid artery diameter; IMT,
14
15 Intima Media Thickness; IMPROVE, IMT-Progression as Predictors of Vascular Events in a
16
17 High Risk European Population; KODE, keto-octadecadienoic acid; MUFA, monounsaturated
18
19 fatty acid; PUFA, polyunsaturated fatty acid; QC, quality control; RP, reversed-phase; RT,
20
21 retention time; SAT, saturated fatty acid; SUMMIT, SUrrogate markers for Micro- and
22
23 Macro-vascular hard endpoints for Innovative diabetes Tools consortium
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. <http://www.who.int/mediacentre/factsheets/fs317/en/>
2. Laakso, M., Is Insulin Resistance a Feature of or a Primary Risk Factor for Cardiovascular Disease? *Curr Diab Rep* **2015**, 15, (12), 105.
3. Ioannidis, J. P.; Tzoulaki, I., Minimal and null predictive effects for the most popular blood biomarkers of cardiovascular disease. *Circ Res* **2012**, 110, (5), 658-62.
4. Wang, Z.; Klipfell, E.; Bennett, B. J.; Koeth, R.; Levison, B. S.; Dugar, B.; Feldstein, A. E.; Britt, E. B.; Fu, X.; Chung, Y. M.; Wu, Y.; Schauer, P.; Smith, J. D.; Allayee, H.; Tang, W. H.; DiDonato, J. A.; Lusis, A. J.; Hazen, S. L., Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature* **2011**, 472, (7341), 57-63.
5. Shah, S. H.; Sun, J. L.; Stevens, R. D.; Bain, J. R.; Muehlbauer, M. J.; Pieper, K. S.; Haynes, C.; Hauser, E. R.; Kraus, W. E.; Granger, C. B.; Newgard, C. B.; Califf, R. M.; Newby, L. K., Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease. *Am Heart J* **2012**, 163, (5), 844-850 e1.
6. Wurtz, P.; Raiko, J. R.; Magnussen, C. G.; Soinen, P.; Kangas, A. J.; Tynkkynen, T.; Thomson, R.; Laatikainen, R.; Savolainen, M. J.; Laurikka, J.; Kuukasjarvi, P.; Tarkka, M.; Karhunen, P. J.; Jula, A.; Viikari, J. S.; Kahonen, M.; Lehtimaki, T.; Juonala, M.; Ala-Korpela, M.; Raitakari, O. T., High-throughput quantification of circulating metabolites improves prediction of subclinical atherosclerosis. *Eur Heart J* **2012**, 33, (18), 2307-16.
7. Stegeman, C.; Pechlaner, R.; Willeit, P.; Langley, S. R.; Mangino, M.; Mayr, U.; Menni, C.; Moayyeri, A.; Santer, P.; Rungger, G.; Spector, T. D.; Willeit, J.; Kiechl, S.; Mayr, M., Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study. *Circulation* **2014**, 129, (18), 1821-31.
8. Wurtz, P.; Havulinna, A. S.; Soinen, P.; Tynkkynen, T.; Prieto-Merino, D.; Tillin, T.; Ghorbani, A.; Artati, A.; Wang, Q.; Tiainen, M.; Kangas, A. J.; Kettunen, J.; Kaikkonen, J.; Mikkila, V.; Jula, A.; Kahonen, M.; Lehtimaki, T.; Lawlor, D. A.; Gaunt, T. R.; Hughes, A. D.; Sattar, N.; Illig, T.; Adamski, J.; Wang, T. J.; Perola, M.; Ripatti, S.; Vasan, R. S.; Raitakari, O. T.; Gerszten, R. E.; Casas, J. P.; Chaturvedi, N.; Ala-Korpela, M.; Salomaa, V., Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. *Circulation* **2015**, 131, (9), 774-85.
9. Wang, T. J.; Larson, M. G.; Vasan, R. S.; Cheng, S.; Rhee, E. P.; McCabe, E.; Lewis, G. D.; Fox, C. S.; Jacques, P. F.; Fernandez, C.; O'Donnell, C. J.; Carr, S. A.; Mootha, V. K.; Florez, J. C.; Souza, A.; Melander, O.; Clish, C. B.; Gerszten, R. E., Metabolite profiles and the risk of developing diabetes. *Nat Med* **2011**, 17, (4), 448-53.
10. Floegel, A.; Stefan, N.; Yu, Z.; Muehlenbruch, K.; Drogan, D.; Joost, H. G.; Fritsche, A.; Haring, H. U.; Hrahe de Angelis, M.; Peters, A.; Roden, M.; Prehn, C.; Wang-Sattler, R.; Illig, T.; Schulze, M. B.; Adamski, J.; Boeing, H.; Pischon, T., Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. *Diabetes* **2013**, 62, (2), 639-48.
11. Alshehry, Z. H.; Mundra, P. A.; Barlow, C. K.; Mellett, N. A.; Wong, G.; McConville, M. J.; Simes, J.; Tonkin, A. M.; Sullivan, D. R.; Barnes, E. H.; Nestel, P. J.; Kingwell, B. A.; Marre, M.; Neal, B.; Poulter, N. R.; Rodgers, A.; Williams, B.; Zoungas, S.; Hillis, G. S.; Chalmers, J.; Woodward, M.; Meikle, P. J., Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus. *Circulation* **2016**, 134, (21), 1637-1650.

12. Ruiz-Canela, M.; Hruby, A.; Clish, C. B.; Liang, L.; Martinez-Gonzalez, M. A.; Hu, F. B., Comprehensive Metabolomic Profiling and Incident Cardiovascular Disease: A Systematic Review. *J Am Heart Assoc* **2017**, 6, (10).
13. Guasch-Ferre, M.; Hruby, A.; Toledo, E.; Clish, C. B.; Martinez-Gonzalez, M. A.; Salas-Salvado, J.; Hu, F. B., Metabolomics in Prediabetes and Diabetes: A Systematic Review and Meta-analysis. *Diabetes Care* **2016**, 39, (5), 833-46.
14. Baldassarre, D.; Hamsten, A.; Veglia, F.; de Faire, U.; Humphries, S. E.; Smit, A. J.; Giral, P.; Kurl, S.; Rauramaa, R.; Mannarino, E.; Grossi, E.; Paoletti, R.; Tremoli, E., Measurements of carotid intima-media thickness and of interadventitia common carotid diameter improve prediction of cardiovascular events: results of the IMPROVE (Carotid Intima Media Thickness [IMT] and IMT-Progression as Predictors of Vascular Events in a High Risk European Population) study. *Journal of the American College of Cardiology* **2012**, 60, (16), 1489-99.
15. Elias, I.; Ferre, T.; Vila, L.; Munoz, S.; Casellas, A.; Garcia, M.; Molas, M.; Agudo, J.; Roca, C.; Ruberte, J.; Bosch, F.; Franckhauser, S., Alox5ap overexpression in adipose tissue leads to LXA4 production and protection against diet-induced obesity and insulin resistance. *Diabetes* **2016**.
16. Araujo, A. C.; Wheelock, C. E.; Haeggstrom, J. Z., The eicosanoids, redox regulated lipid mediators in immunometabolic disorders. *Antioxid Redox Signal* **2017**.
17. Capra, V.; Back, M.; Barbieri, S. S.; Camera, M.; Tremoli, E.; Rovati, G. E., Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke. *Med Res Rev* **2013**, 33, (2), 364-438.
18. Looker, H. C.; Colombo, M.; Agakov, F.; Zeller, T.; Groop, L.; Thorand, B.; Palmer, C. N.; Hamsten, A.; de Faire, U.; Nogoceke, E.; Livingstone, S. J.; Salomaa, V.; Leander, K.; Barbarini, N.; Bellazzi, R.; van Zuydam, N.; McKeigue, P. M.; Colhoun, H. M.; Investigators, S., Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes. *Diabetologia* **2015**, 58, (6), 1363-71.
19. Baldassarre, D.; Nyyssonen, K.; Rauramaa, R.; de Faire, U.; Hamsten, A.; Smit, A. J.; Mannarino, E.; Humphries, S. E.; Giral, P.; Grossi, E.; Veglia, F.; Paoletti, R.; Tremoli, E.; group, I. s., Cross-sectional analysis of baseline data to identify the major determinants of carotid intima-media thickness in a European population: the IMPROVE study. *Eur Heart J* **2010**, 31, (5), 614-22.
20. Kamleh, M. A.; Snowden, S. G.; Grapov, D.; Blackburn, G. J.; Watson, D. G.; Xu, N.; Stahle, M.; Wheelock, C. E., LC-MS metabolomics of psoriasis patients reveals disease severity-dependent increases in circulating amino acids that are ameliorated by anti-TNFalpha treatment. *J Proteome Res* **2015**, 14, (1), 557-66.
21. Balgoma, D.; Yang, M.; Sjodin, M.; Snowden, S.; Karimi, R.; Levanen, B.; Merikallio, H.; Kaarteenaho, R.; Palmberg, L.; Larsson, K.; Erle, D. J.; Dahlen, S. E.; Dahlen, B.; Skold, C. M.; Wheelock, A. M.; Wheelock, C. E., Linoleic acid-derived lipid mediators increase in a female-dominated subphenotype of COPD. *Eur Respir J* **2016**, 47, (6), 1645-56.
22. Checa, A.; Holm, T.; Sjodin, M. O.; Reinke, S. N.; Alm, J.; Scheynius, A.; Wheelock, C. E., Lipid mediator profile in vernix caseosa reflects skin barrier development. *Sci Rep* **2015**, 5, 15740.
23. Chambers, M. C.; Maclean, B.; Burke, R.; Amodei, D.; Ruderman, D. L.; Neumann, S.; Gatto, L.; Fischer, B.; Pratt, B.; Egertson, J.; Hoff, K.; Kessner, D.; Tasman, N.; Shulman, N.;

1
2
3 Frewen, B.; Baker, T. A.; Brusniak, M. Y.; Paulse, C.; Creasy, D.; Flashner, L.; Kani, K.;
4 Moulding, C.; Seymour, S. L.; Nuwaysir, L. M.; Lefebvre, B.; Kuhlmann, F.; Roark, J.;
5 Rainer, P.; Detlev, S.; Hemenway, T.; Huhmer, A.; Langridge, J.; Connolly, B.; Chadick, T.;
6 Holly, K.; Eckels, J.; Deutsch, E. W.; Moritz, R. L.; Katz, J. E.; Agus, D. B.; MacCoss, M.;
7 Tabb, D. L.; Mallick, P., A cross-platform toolkit for mass spectrometry and proteomics. *Nat*
8 *Biotechnol* **2012**, 30, (10), 918-20.

9
10 24. Smith, C. A.; Want, E. J.; O'Maille, G.; Abagyan, R.; Siuzdak, G., XCMS: processing
11 mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching,
12 and identification. *Anal Chem* **2006**, 78, (3), 779-87.

13 25. Wishart, D. S.; Tzur, D.; Knox, C.; Eisner, R.; Guo, A. C.; Young, N.; Cheng, D.;
14 Jewell, K.; Arndt, D.; Sawhney, S.; Fung, C.; Nikolai, L.; Lewis, M.; Coutouly, M.-A.;
15 Forsythe, I.; Tang, P.; Shrivastava, S.; Jeroncio, K.; Stothard, P.; Amegbey, G.; Block, D.;
16 Hau, D. D.; Wagner, J.; Miniaci, J.; Clements, M.; Gebremedhin, M.; Guo, N.; Zhang, Y.;
17 Duggan, G. E.; MacInnis, G. D.; Weljie, A. M.; Dowlatabadi, R.; Bamforth, F.; Clive, D.;
18 Greiner, R.; Li, L.; Marrie, T.; Sykes, B. D.; Vogel, H. J.; Querengesser, L., HMDB: the
19 Human Metabolome Database. *Nucleic Acids Research* **2007**, 35, (suppl 1), D521-D526.

20 26. Armitage, P.; Berry, G.; Matthews, J. N. S., *Statistical methods in medical research*. 4th
21 ed.; Blackwell Science: Malden, MA, 2001; p xi, 817.

22 27. Schatz, M.; Mosen, D.; Apter, A. J.; Zeiger, R. S.; Vollmer, W. M.; Stibolt, T. B.;
23 Leong, A.; Johnson, M. S.; Mendoza, G.; Cook, E. F., Relationships among quality of life,
24 severity, and control measures in asthma: an evaluation using factor analysis. *J Allergy Clin*
25 *Immunol* **2005**, 115, (5), 1049-55.

26 28. Baldassarre, D.; Hamsten, A.; Veglia, F.; de Faire, U.; Humphries, S. E.; Smit, A. J.;
27 Giral, P.; Kurl, S.; Rauramaa, R.; Mannarino, E.; Grossi, E.; Paoletti, R.; Tremoli, E.; Group,
28 I. S., Measurements of carotid intima-media thickness and of interadventitia common carotid
29 diameter improve prediction of cardiovascular events: results of the IMPROVE (Carotid
30 Intima Media Thickness [IMT] and IMT-Progression as Predictors of Vascular Events in a
31 High Risk European Population) study. *J Am Coll Cardiol* **2012**, 60, (16), 1489-99.

32 29. Kondreddy, V. K.; Anikisetty, M.; Naidu, K. A., Medium-chain triglycerides and
33 monounsaturated fatty acids potentiate the beneficial effects of fish oil on selected
34 cardiovascular risk factors in rats. *The Journal of nutritional biochemistry* **2016**, 28, 91-102.

35 30. Parlesak, A.; Eckoldt, J.; Winkler, K.; Bode, C. J.; Schafer, C., Intercorrelations of
36 lipoprotein subfractions and their covariation with lifestyle factors in healthy men. *Journal of*
37 *clinical biochemistry and nutrition* **2014**, 54, (3), 174-80.

38 31. Guasch-Ferre, M.; Babio, N.; Martinez-Gonzalez, M. A.; Corella, D.; Ros, E.; Martin-
39 Pelaez, S.; Estruch, R.; Aros, F.; Gomez-Gracia, E.; Fiol, M.; Santos-Lozano, J. M.; Serra-
40 Majem, L.; Bullo, M.; Toledo, E.; Barragan, R.; Fito, M.; Gea, A.; Salas-Salvado, J., Dietary
41 fat intake and risk of cardiovascular disease and all-cause mortality in a population at high
42 risk of cardiovascular disease. *The American journal of clinical nutrition* **2015**, 102, (6),
43 1563-73.

44 32. Sun, Y.; Koh, H. W.; Choi, H.; Koh, W. P.; Yuan, J. M.; Newman, J. W.; Su, J.; Fang,
45 J.; Ong, C. N.; van Dam, R. M., Plasma fatty acids, oxylipins, and risk of myocardial
46 infarction: the Singapore Chinese Health Study. *J Lipid Res* **2016**, 57, (7), 1300-7.

47 33. Sun, Y.; Koh, W. P.; Yuan, J. M.; Choi, H.; Su, J.; Ong, C. N.; van Dam, R. M., Plasma
48 alpha-Linolenic and Long-Chain omega-3 Fatty Acids Are Associated with a Lower Risk of
49 Acute Myocardial Infarction in Singapore Chinese Adults. *J Nutr* **2016**, 146, (2), 275-82.

- 1
2
3 34. Floegel, A.; Kuhn, T.; Sookthai, D.; Johnson, T.; Prehn, C.; Rolle-Kampczyk, U.; Otto,
4 W.; Weikert, C.; Illig, T.; von Bergen, M.; Adamski, J.; Boeing, H.; Kaaks, R.; Pischon, T.,
5 Serum metabolites and risk of myocardial infarction and ischemic stroke: a targeted
6 metabolomic approach in two German prospective cohorts. *Eur J Epidemiol* **2017**.
- 7
8 35. Baldassarre, D.; Veglia, F.; Hamsten, A.; Humphries, S. E.; Rauramaa, R.; de Faire, U.;
9 Smit, A. J.; Giral, P.; Kurl, S.; Mannarino, E.; Grossi, E.; Paoletti, R.; Tremoli, E.; Group, I.
10 S., Progression of carotid intima-media thickness as predictor of vascular events: results from
11 the IMPROVE study. *Arterioscler Thromb Vasc Biol* **2013**, 33, (9), 2273-9.
- 12
13 36. Schwab, U.; Lauritzen, L.; Tholstrup, T.; Haldorssoni, T.; Riserus, U.; Uusitupa, M.;
14 Becker, W., Effect of the amount and type of dietary fat on cardiometabolic risk factors and
15 risk of developing type 2 diabetes, cardiovascular diseases, and cancer: a systematic review.
16 *Food Nutr Res* **2014**, 58.
- 17
18 37. Imae, M.; Asano, T.; Murakami, S., Potential role of taurine in the prevention of
19 diabetes and metabolic syndrome. *Amino Acids* **2014**, 46, (1), 81-8.
- 20
21 38. Murakami, S., Taurine and atherosclerosis. *Amino Acids* **2014**, 46, (1), 73-80.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Basic characteristics of the study participants

	Diabetics		Non-diabetics	
	Cases	Controls	Cases	Controls
N	40	39	133	133
Age, years*	66.5 (61.5 - 68.4)	65.5 (61.2 - 68.8)	65.5 (60.4 - 68.1)	65.2 (60.2 - 67.5)
Sex (F/M), n (% of females)*	15/25, (38)	16/23, (41)	51/82, (38)	51/82, (38)
BMI, kg/m ²	29.3 (26.9 - 32.2)	28.1 (24.8 - 32.4)	26.4 (24.1 - 29.3)	27.0 (24.4 - 29.3)
Waist-hip ratio	0.96 (0.92 - 1.00)	0.95 (0.90 - 1.01)	0.94 (0.87 - 0.98)	0.93 (0.88 - 0.97)
Waist, cm	101 (97 - 113)	98 (91 - 111)	95 (86 - 100)	96 (87 - 102)
SBP, mmHg	142 (133 - 153)	146 (136 - 160)	144 (131 - 156)	144 (130 - 160)
DBP, mmHg	83 (77 - 87)	85 (81 - 88)	82 (76 - 90)	83 (77 - 90)
Cholesterol, mmol/L	4.98 (4.49 - 5.77)	4.93 (4.54 - 5.75)	5.66 (5.01 - 6.41)	5.49 (4.94 - 6.31)
LDL cholesterol, mmol/L	3.06 (2.63 - 3.72)	3.06 (2.57 - 3.71)	3.78 (3.05 - 4.50)	3.51 (2.79 - 4.21)
HDL cholesterol, mmol/L	1.05 (0.93 - 1.27)	1.03 (0.91 - 1.27)	1.18 (1.04 - 1.44)	1.21 (1.03 - 1.51)
Triglycerides, mmol/L	1.94 (1.31 - 2.58)	1.52 (1.09 - 2.01)	1.39 (1.04 - 1.93)	1.44 (0.97 - 2.16)
Glucose, mmol/L	7.56 (6.61 - 9.05)	7.50 (6.65 - 9.75)	5.40 (4.87 - 5.75)	5.40 (4.90 - 5.90)
CRP, mg/mL	2.12 (1.20 - 4.23)	2.01 (0.91 - 3.42)	2.19 (0.97 - 4.42)	1.66 (0.87 - 3.22)
Smoking, n (%)*	7 (17.5)	8 (20.5)	27 (20.5)	27 (20.5)
Pack years, number	15 (0 - 30)	0 (0 - 18)	0 (0 - 17)	0 (0 - 18)
Diseases				
Diabetes, n (%)*	40 (100)	39 (100)	-	-
Hypercholesterolemia, n (%)	24 (60.0)	23 (60.5)	92 (69.7)	91 (68.4)
Hypertriglyceridemia, n (%)	17 (42.5)	9 (23.1)	30 (22.7)	32 (24.1)
Hypoalphalipoproteinemia, n (%)	8 (20.0)	5 (12.8)	22 (16.7)	12 (9.0)
Hypertension, n (%)	36 (90.0)	32 (82.1)	108 (81.8)	105 (79.0)
Medication, n (%)	40 (100.0)	35 (89.7)	113 (85.6)	107 (80.5)
Glucose-lowering, n (%)	29 (72.5)	25 (64.1)	0	0
Insulin, n (%)*	5 (12.5)	5 (12.8)	0	0
Lipid lowering, n (%)	20 (50.0)	18 (46.2)	55 (42.6)	57 (43.2)
Statin, n (%)*	18 (45.0)	17 (43.6)	46 (34.9)	47 (35.3)
Anti-hypertension, n (%)	29 (72.5)	22 (56.4)	74 (56.1)	73 (54.9)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Anti-platelet, n (%)	17 (42.5)	7 (18.0)	30 (22.7)	19 (14.3)
Events	43		145	
Cardiac	28 (65.1)	-	77 (53.1)	-
Cerebro-vascular	10 (35.7)	-	50 (34.5)	-
Peripheral	5 (11.1)	-	18 (12.4)	-

F, females; M, males; BMI, body-mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low density lipoprotein; HDL, high density lipoprotein; CRP, C-reactive protein.

Smoking refers to ever smoker vs non-smokers.

Lipid-lowering medication includes statin, fibrate and resin. Also, 4 cases (2 diabetics, 2 non-diabetics) and 1 non-diabetic control used fish oil.

Total event number is higher than number of cases due to multiple events in some of the cases.

*Matching variables.

Table 2. Prediction of cardiovascular events estimated for individual factors

Factor	Crude Diabetics			Crude Non-diabetics			Adjusted Diabetics [†]			Adjusted Non-diabetics		
	OR	95% CI	p-value	OR	95% CI	p-value	OR	95% CI	p-value	OR	95% CI	p-value
F1	0.69	0.30-1.64	0.404	0.66	0.46-0.96	0.029	0.86	0.32-2.20	0.759	0.64	0.43-0.95	0.026
F2	1.39	0.25-7.82	0.711	0.65	0.27-1.57	0.341	1.22	0.13-9.35	0.851	0.62	0.23-1.50	0.309
F3	0.36	0.11-1.15	0.085	0.58	0.35-0.95	0.031	0.36	0.06-1.08	0.108	0.63	0.38-1.09	0.087
F4	0.51	0.09-2.85	0.446	0.58	0.31-1.06	0.076	0.50	0.08-5.51	0.495	0.65	0.33-1.20	0.179
F5	0.86	0.51-1.46	0.578	0.79	0.59-1.06	0.122	0.93	0.31-1.39	0.815	0.81	0.58-1.10	0.195
F6	0.93	0.40-1.49	0.653	0.77	0.68-1.28	0.443	0.78	0.33-1.60	0.519	0.96	0.69-1.34	0.787

F1-6 are derived from factor analysis of the concatenated metabolomics and lipid mediator data sets. OR, odds ratio; 95% CI, 95% confidence interval.

[†]Adjustment for age, body-mass index, hypertension, HDL cholesterol and anti-platelet medication was introduced in the regression model for each factor.

Table 3. Relationships of free fatty acids within Factor 1 to future cardiovascular events.

	Diabetics			Non-diabetics		
	HR*	95% CI	p-value	HR	95% CI	p-value
Factor 1	1.01	0.61-1.67	0.966	0.80	0.65-0.97	0.024
Omega-3 fatty acids						
Docosahexaenoic acid	1.04	0.70-1.53	0.85	0.86	0.72-1.02	0.085
Omega-6 fatty acids						
γ-Linolenic acid	1.01	0.65-1.58	0.957	0.72	0.59-0.88	0.001
Linoleic acid	0.87	0.58-1.29	0.481	0.83	0.69-1.00	0.053
Arachidonic acid	1.05	0.0.69-1.60	0.815	0.83	0.70-0.99	0.037
Adrenic acid	1.01	0.67-1.52	0.967	0.79	0.66-0.95	0.012
Dihomo-γ-Linolenic acid	0.99	0.65-1.52	0.986	0.81	0.69-0.96	0.015
Omega-7 fatty acids						
Palmitoleic acid	0.77	0.	0.199	0.87	0.73-1.05	0.143
Omega-9 fatty acids						
Oleic acid	1.03	0.71-1.51	0.841	0.83	0.70-0.98	0.030
Mead acid	0.82	0.56-1.21	0.316	0.85	0.72-1.01	0.059
Saturated fatty acids						
Stearic acid	1.02	0.73-1.43	0.891	0.81	0.68-0.96	0.016
Palmitic acid	1.03	0.73-1.46	0.874	0.79	0.66-0.94	0.009

*Hazard ratios (HR) are per 1-SD log transformed metabolite concentration and adjusted for age, sex, geographical latitude, hypertension, ever smoking, and anti-platelet medication. 95% CI, 95% confidence interval.

Table 4. Associations between individual components of Factor 1 with change over time in inter-adventitia common carotid artery diameter (ICCAD) in non-diabetics (n=197).[†]

	β	SE	p
12(13)-EpOME	-0.018	0.005	0.001
N-Stearoyl Taurine	-0.008	0.002	0.001
13-HODE	-0.018	0.005	0.001
13-KODE	-0.014	0.004	0.002
9-HODE	-0.017	0.005	0.002
N-Palmitoyl Taurine	-0.011	0.004	0.009
LEA	-0.011	0.005	0.030
9(10)-EpOME	-0.010	0.005	0.045
9-HOTrE	-0.006	0.003	0.050
γ -Linoleic acid	-0.008	0.004	0.055
9-KODE	-0.008	0.004	0.060
15-HETE	-0.008	0.005	0.064
Arachidonyl glycine	-0.004	0.002	0.070
AEA	-0.007	0.004	0.073
Dihomo- γ -Linolenic acid	-0.007	0.004	0.096
Palmitic acid	-0.009	0.005	0.099
15-KETE	-0.009	0.005	0.100
Stearic acid	-0.011	0.006	0.103
OEA	-0.010	0.006	0.110
11(12)-EpETrE	-0.008	0.005	0.114
C20H36O3_HEDE(s)*	-0.003	0.002	0.115
Oleic acid	-0.008	0.005	0.136
Arachidonic acid	-0.008	0.005	0.147
17-HDoHE	-0.006	0.004	0.147
Docosahexaenoic Acid	-0.005	0.004	0.211
1-Stearoyl-2-Arachidonoyl PC	-0.005	0.004	0.239
Adrenic acid	-0.004	0.004	0.330
PEA	-0.006	0.007	0.339
C20H32O3_HETE(s)*	-0.003	0.003	0.353
Arachidonoyl PAF C-16	-0.004	0.005	0.372
5-HETE	-0.003	0.005	0.466
Mead acid	0.001	0.002	0.506
EKODE	-0.001	0.002	0.562
DIHOMOLEA	0.002	0.004	0.636
5-KETE	0.001	0.004	0.785
9-KOTrE	-0.001	0.003	0.807
Palmitoleic acid	0.001	0.006	0.908
8-HDoHE	<0.001	0.004	0.917
15-HETrE	<0.001	0.004	0.982

[†]Values are from linear regression with adjustment for age, gender and corresponding baseline values. Metabolite nomenclature is provided in Table S1. SE=standard error.


*The terminology of C20H36O3_HEDE(s) and C20H32O3_HETE(s) indicates that the reported metabolite is a mono-hydroxy isomer of either eicosadienoic acid or arachidonic acid, respectively; however, the exact position of the hydroxyl group is undetermined.

Figure Legends

Figure 1. Study design with participant inclusion and matching criteria. Cases were subjects who suffered a cardiovascular event (myocardial infarction, sudden cardiac death, angina pectoris, ischemic stroke, transient ischemic attack, new diagnosis of intermittent claudication, heart failure, or any surgical intervention or revascularization of coronary or peripheral arteries) during the follow up period.

Figure 2. Association of the free fatty acids within Factor 1 with incidence of cardiovascular events stratified by diabetes status. In non-diabetics, high concentrations of fatty acids were associated with lower odds to suffer cardiovascular events (OR=0.65, 0.27-0.80 95% CI, p=0.030). Linoleic acid was manually added given its relevance to cardiovascular disease, even though the loadings were below the <0.4 cutoff.

Graphical Abstract






Figure 1. Study design with participant inclusion and matching criteria. Cases were subjects who suffered a cardiovascular event (myocardial infarction, sudden cardiac death, angina pectoris, ischemic stroke, transient ischemic attack, new diagnosis of intermittent claudication, heart failure, or any surgical intervention or revascularization of coronary or peripheral arteries) during the follow up period.

160x139mm (300 x 300 DPI)





Figure 2. Association of the free fatty acids within Factor 1 with incidence of cardiovascular events stratified by diabetes status. In non-diabetics, high concentrations of fatty acids were associated with lower odds to suffer cardiovascular events (OR=0.65, 0.27-0.80 95% CI, $p=0.030$). Linoleic acid was manually added given its relevance to cardiovascular disease, even though the loadings were below the <0.4 cutoff.

152x78mm (300 x 300 DPI)



Graphical Abstract

114x55mm (300 x 300 DPI)